![Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]](/content/dam/biopharm/esperoct/global/esperoct-logo.png){kind=logo}
Combining FVIII with PEGylation technology, Esperoct® provides high factor levels and longer protection against bleeds.a
Ask your doctor about a switch to Esperoct®.
Experience the Esperoct® difference with less frequent dosing and longer lasting factor.
This is the prophylaxis offering high factor levels from one dose to the next in adults and adolescents.
aCompared with SHL products.
bTrough level goal is 1% for prophylaxis.
cData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18years) were 2.7 IU/dL.
dSteady-state factor VIII (FVIII) activity levels were estimated in 143 adults and adolescents using PK modeling.
What is half-life?
Half-life is the time it takes for the level of factor in the blood to fall by half.
What is half-life?
Half-life is the time it takes for the level of factor in the blood to fall by half.
Switch to fewer infusions.
Compared with standard half-life dosing schedules, the simple, fixed dosing routine of Esperoct® calls for fewer infusions per year.
No dose adjustment needed.
If you previously infused every other day
If you previously infused 3x/week
No dose adjustment needed.e
If your child previously infused every other day
If your child previously infused 3x/week
eInterval can be adjusted based on individual response to treatment.
A MASAC recommendation.
The Medical and Scientific Advisory Council (MASAC) recommends that prophylaxis factor be considered optimal therapy for people with severe hemophilia A.
Esperoct® goes where you go.
Recombinant factor VIII Esperoct® can be used in situations where bleeding may happen:
- As a prophylaxis treatment for hemophilia A
- Used on-demand for sudden bleeds
- Used in and after surgery
HCL Connect.
Questions about switching to Esperoct®? Connect with your Hemophilia Community Liaison (HCL) for personalized support in your journey with hemophilia A. Find your HCL now.
Your questions, answered.
Question: What is a trough level?
Answer: Factor in the bloodstream rises and falls in patients treated prophylactically with factor. It is highest right after an infusion and lowest right before an infusion. The low level right before infusion is called the trough level. Many factor products aim to keep trough levels at 1%. In a study of adults and adolescents who were treated with Esperoct® for prophylaxis, researchers found that extended half-life Esperoct® keeps trough levels at or above 3% all of the time, and 5% approximately 90% of the time.b,c,d
Question: What is MASAC (Medical and Scientific Advisory Council), the group that recommends prophylaxis factor as the optimal therapy for hemophilia A?
Answer: This branch of the National Hemophilia Foundation (NHF) is a group of physicians, researchers, and other medical professionals—all with expertise in bleeding disorders and infectious diseases—who meet twice a year with consumers and representatives from the NHF. The group issues treatment and research guidelines for the bleeding disorder community. Medical schools, pharmacists, insurance companies and many others then use MASAC’s guidance in their decision making.